Splenic Marginal Zone Lymphoma

Showing NaN - NaN of 7

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +20 more
  • Scottsdale, Arizona
  • +1 more
May 6, 2022

Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma Trial in

Completed
  • Adult Nasal Type Extranodal NK/T-cell Lymphoma
  • +18 more
  • Scottsdale, Arizona
  • +1 more
Sep 28, 2020

Anaplastic Large Cell Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Mature T-Cell and

Completed
  • Anaplastic Large Cell Lymphoma
  • +12 more
  • Iowa City, Iowa
  • +1 more
Apr 3, 2020

Cutaneous B-cell Non-Hodgkin Lymphoma, MALT, Nodal Marginal Zone B-cell Lymphoma Trial in Rochester (biological, procedure,

Completed
  • Cutaneous B-cell Non-Hodgkin Lymphoma
  • +15 more
  • dendritic cell vaccine therapy
  • +6 more
  • Rochester, Minnesota
    Mayo Clinic
Jan 13, 2020

Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Grade 1

Completed
  • Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
  • +8 more
  • Scottsdale, Arizona
  • +1 more
Apr 4, 2019

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Rochester (rituximab, yttrium Y 90

Terminated
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +8 more
  • rituximab
  • +4 more
  • Rochester, Minnesota
    Mayo Clinic
Jul 9, 2018

MALT, Nodal Marginal Zone B-cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma Trial in Rochester (biological, other,

Completed
  • Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue
  • +6 more
  • rituximab
  • +4 more
  • Rochester, Minnesota
    North Central Cancer Treatment Group
Aug 23, 2013